HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rothe, A. Articles by Power, B. E. Search for Related Content PubMed PubMed Citation Articles by Rothe, A. Articles by Power, B. E.

In vitro display technologies reveal novel biopharmaceutics

Achim Rothe^*, Ralf J. Hosse and Barbara E. Power^*,,1

^* CSIRO Molecular and Health Technologies,

Preventative Health National Research Flagship, Parkville, Victoria, Australia

¹Correspondence: CSIRO Molecular and Health Technologies, Protein Design for Diagnostics, 343 Royal Parade, Parkville, Victoria 3052, Australia. E-mail: barbara.power{at}csiro.au

Display technologies are fundamental to the isolation of specific high-affinity binding proteins for diagnostic and therapeutic applications in cancer, neurodegenerative, and infectious diseases as well as autoimmune and inflammatory disorders. Applications extend into the broad field of antibody (Ab) engineering, synthetic enzymes, proteomics, and cell-free protein synthesis. Recently, in vitro display technologies have come to prominence due to the isolation of high-affinity human antibodies by phage display, the development of novel scaffolds for ribosome display, and the discovery of novel protein-protein interactions. In vitro display represents an emerging and innovative technology for the rapid isolation and evolution of high-affinity peptides and proteins. So far, only one clinical drug candidate produced by in vitro display technology has been approved by the FDA for use in humans, but several are in clinical or preclinical testing. This review highlights recent advances in various engineered biopharmaceutical products isolated by in vitro display with a focus on the commercial developments.—Rothe, A., Hosse, R. J., Power, B. E. In vitro display technologies reveal novel biopharmaceutics.

Key Words: Ab engineering • scaffold • high affinity

This article has been cited by other articles:

				Y.-J. Lee, H.-J. Choi, J.-S. Lim, J.-H. Earm, B.-H. Lee, I.-S. Kim, J. Frokiaer, S. Nielsen, and T.-H. Kwon A novel method of ligand peptidomics to identify peptide ligands binding to AQP2-expressing plasma membranes and intracellular vesicles of rat kidney Am J Physiol Renal Physiol, July 1, 2008; 295(1): F300 - F309. [Abstract] [Full Text] [PDF]

				Z. Cheng, O. P. De Jesus, M. Namavari, A. De, J. Levi, J. M. Webster, R. Zhang, B. Lee, F. A. Syud, and S. S. Gambhir Small-Animal PET Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with Site-Specific 18F-Labeled Protein Scaffold Molecules J. Nucl. Med., May 1, 2008; 49(5): 804 - 813. [Abstract] [Full Text] [PDF]

				W. Mier, S. Zitzmann, S. Kramer, J. Reed, E.-M. Knapp, A. Altmann, M. Eisenhut, and U. Haberkorn Influence of Chelate Conjugation on a Newly Identified Tumor-Targeting Peptide J. Nucl. Med., September 1, 2007; 48(9): 1545 - 1552. [Abstract] [Full Text] [PDF]